Peginterferon Beta-1A
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Peginterferon Beta-1A |
| DrugBank ID | DB09122 |
| Brand Names (EU) | Plegridy |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.71% |
Approved Indication (EMA)
Treatment of relapsing remitting multiple sclerosis in adult patients.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | relapsing-remitting multiple sclerosis | 99.71% | DL |
| 2 | heart neoplasm | 94.10% | DL |
| 3 | congenital anomaly of ventricular septum | 89.33% | DL |
| 4 | heart conduction disease | 89.26% | DL |
| 5 | borderline ovarian serous tumor | 88.87% | DL |
| 6 | rete ovarii cystadenoma | 88.76% | DL |
| 7 | ovarian mucinous cystadenofibroma | 88.44% | DL |
| 8 | ovarian benign neoplasm | 88.36% | DL |
| 9 | ovarian papillary cystadenoma | 88.18% | DL |
| 10 | malignant ovarian Brenner tumor | 88.06% | DL |
| 11 | pericardium disease | 88.05% | DL |
| 12 | serous neoplasm | 88.00% | DL |
| 13 | ovarian surface papilloma | 87.96% | DL |
| 14 | mucinous ovarian cystadenoma | 87.93% | DL |
| 15 | cardiovascular disease | 87.76% | DL |
| 16 | cardiac anomalies-heterotaxy syndrome | 86.21% | DL |
| 17 | heart aneurysm | 86.21% | DL |
| 18 | myocardial rupture | 86.21% | DL |
| 19 | cor biloculare | 86.21% | DL |
| 20 | carcinoid heart disease | 86.21% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.